Unaffordable is What Happens When Flu Treatments are Patented
This isn't the really interesting news I promised the other day (that's still being vetted elsewhere); but it's pretty darn telling.
(Above: What it would cost different regions to stockpile Tamiflu under Roche's plan.)
Roche and Glaxo, with their flu antivirals Tamiflu and Relenza (respectively), are offering us a little preview of what's going to happen with pandemic vaccines (and other biologicals) if the patent trend continues unabated. What happens, in a phrase, is that the rich get treated and the poor get dead.
Today's news brings an item about Roche and Glaxo's hawking of their drugs to corporations for private stockpiles. Think of it as a sort of pandemic "health insurance", mega-corporation style. (More)
About Immunocompetent
I am weary of public health G.I. Joes (and Janes) and other obsessives and their threats that we're all gonna die of bird flu.
I am turned off by the callous and poorly reasoned bashing of foreigners that fills many flu blogs.
I believe that greed and poor governance in the US and EU plays a huge and underexplored role in the sad state of global readiness for a flu pandemic.
I am sure that national security and public health ought not to be mixed up in the way they have become.
Immunocompetent is a place for enlightened talk about Bird Flu, and where xenophobia and fearmongering are banned.
Here you will find fresh perspective about the serious problem of potentially pandemic influenza. You'll get information and analysis that you won't find blogged elsewhere, because this site doesn't just comment on the news, it aims to make it.
From 1999 to 2008 your host, Edward Hammond, directed the Sunshine Project, a nongovernmental organization focusing on biological weapons and biosafety. He first stuck his toe into influenza issues in 2003, when the Sunshine Project issued one of the first public warnings that US scientists were intending to recreate 1918 influenza. Since 2006 he has focused on H5N1 issues, specifically, questions of access and benefit sharing related to influenza viruses.